{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.010","upperLimit":"0.052","value":"0.0278"},{"groupId":"OG001","lowerLimit":"0.021","upperLimit":"0.088","value":"0.0264"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"title":"Cycle 1, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.014","upperLimit":"0.054","value":"0.0285"},{"groupId":"OG001","lowerLimit":"0.014","upperLimit":"0.084","value":"0.0264"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"title":"Cycle 1, Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.011","upperLimit":"0.042","value":"0.0264"},{"groupId":"OG001","lowerLimit":"0.015","upperLimit":"0.074","value":"0.0264"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"title":"Cycle 2, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.020","upperLimit":"0.115","value":"0.0285"},{"groupId":"OG001","lowerLimit":"0.010","upperLimit":"0.047","value":"0.0257"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"title":"Cycle 2, Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"description":"Tmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.","dispersionType":"Full Range","groups":[{"description":"Participants in Cohort 1 had received prior treatment with platinum-containing chemotherapy. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.","id":"OG000","title":"Enfortumab Vedotin - Cohort 1"},{"description":"Participants in Cohort 2 had received no platinum-containing chemotherapy were ineligible for treatment with cisplatin at the time of enrollment. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.","id":"OG001","title":"Enfortumab Vedotin - Cohort 2"}],"paramType":"MEDIAN","populationDescription":"PK analysis set: all participants who received enfortumab vedotin and from whom at least one blood sample was collected and assayed for enfortumab vedotin, monomethyl auristatin E (MMAE) or total antibody (Tab) concentration. Corresponding records of the time of dosing and sample collection must also be available for all enfortumab vedotin. Here, 'Number Analyzed'= participants evaluable at specified timepoints.","reportingStatus":"POSTED","timeFrame":"Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22","title":"PK Parameter for Enfortumab Vedotin: Time to Maximum Concentration (Tmax) (Serum)","type":"SECONDARY","unitOfMeasure":"Days"}